Member Info for Pedrobull

matched bargain **************s exist but shares only transact at agreed prices much like aim except the spread will be a lot higher here is an example;

https://jpjenkins.com/our-companies-2/

Available to buy today at 529.4p the last tender offer was 1% below NAV lets say 610p

.

HL Online dealing is now back available and being offered 31.16p to sell 32.9p to buy

Only 1 buyer so far today price 0.616p thanks Mr Market.

GLA

BLU entire market cap is now under £4m even with a crypto bull and owning 27% of Satoshipay?

Gold closed Friday in New York at a new ATH $2091

The Feb contract closed at $2091 on Friday which is new ATH

I also hold Legal & General Gold Mining ETF & Vaneck Junior Gold Miners ETF

The Gold December contract closed the week at $2073 new ATH incoming

Dividend of 1.65p x 4 = 6.6p which give a yield of 6.8% at current 96p

Definitely in an offer period given all the Rule 8.3 of the Takeover Code RNSs which get posted every day.

I'll be happy with 1% under NAV about 85p thank you very much

NAV per Ordinary share decreased by 7.8% to 99.8c (GBp - 86.3p)

Goldman Sachs cuts Dr Martens price target to 124 (145) pence - 'neutral'

Well done anyone buying yesterday in 80s

GLA

I reckon you could phone HL and telephone deal this minimum commission £50 though which is a pain if you've only got a few thousand shares, guess its become a long term hold now!

Online dealing not available

Further to a shareholder meeting which is due to take place on 4 January 2024, this stock is due to delist on 12 January 2024. Buying stock that’s due to delist is very risky and can be difficult for you to sell in the future. If you choose to buy this stock, you do so on the understanding that you’ve read this warning and are aware of the risks.

Looks like BPCR will get $14.5 million unexpected income in 2024.

From the RNS

Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released Thursday 30 November 2023 by AbbVie Inc. ("AbbVie") regarding the definitive agreement pursuant to which AbbVie will acquire ImmunoGen, Inc. ("IMGN") for a total equity value of approximately US$10.1 billion (the "Transaction"). AbbVie and IMGN currently anticipate that the Transaction will close in the middle of 2024.

The Company announced on 11 April 2023 an investment in a senior secured loan to IMGN of up to US$62.5 million in up to two tranches. As of today, the Company had funded the first tranche representing a US$37.5 million investment. The loan is expected to be prepaid upon the closing of the Transaction. Pursuant to the senior secured loan agreement, in connection with the Transaction and the repayment of outstanding principal, the Company is expected to receive a make-whole payment for the remainder of the three-year make-whole period along with a prepayment premium of 3%, in each case with respect to the principal repaid. For illustrative purposes, if the Transaction were to close on 30 June 2024, the Company would be expected to receive approximately US$14.5 million in prepayment and make-whole fees.

They hired a new CFO early this month in November and then promoted a non-exec (also a director at Apple) as the chief brand officer.

.

Is there a 3rd investigation by the Gambling Commission weighing on this?

Still lowly priced

Wouldn't hold out for Mike Ashley he won't be rushing to buy unless the liquidators are in control

I'm sitting on my hands today.

Profit warnings sometimes take a few days to settle

Many UK companies struggle to succeed in the USA.

Also many companies with great products can go down rabbit holes as they try to grow and management execution gets more complicated.

The final dividend must be under pressure else this is a screaming buy.

GLA